A Randomized Phase 2 Study of Single Agent GSK2118436 (BRAFi) vs. Combination Regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 26 Jan 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Dec 2017.